A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 774 participants.
Also called NCT01648582
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 774 participants
- Sponsor
- Registry
-
NCT01648582
-
- Other papers using this trial's data
- Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study
- The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Mexico, Russia, South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01648582. Randomized; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-07-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
- Acronym
- AWARD-CHN2
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Insulin glargine
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Sulfonylureas
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01648582- Content hash
4301bf8d3078f09e78ae0d3082635bd4f1c5cb2c0e789c3a3618ffec6a716cda